An outlook on antigen-specific adoptive immunotherapy for viral infections with a focus on COVID-19

Monzavi, Seyed Mostafa; Naderi, Mahmood; Ahmadbeigi, Naser; Kajbafzadeh, Abdol‐Mohammad; Muhammadnejad, Samad

doi:10.1016/j.cellimm.2021.104398

Cited by 8 publications

(23 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 20 , 21 To isolate functional Ag-specific T cells from PBMC, magnetic-activated peptide-MHC multimer-guided enrichment and magnetic-activated cytokine capture-based sorting have been used as the two methods for reliably reproducible GMP-grade production. 2 , 3 , 13 , 15 Using the latter method, WT1-reactive T cells were enriched and isolated from two groups of healthy donors and patients with Wilms tumor in this study. It was revealed that greater frequencies of these cells can be enriched from patients with Wilms tumor.…”

Section: Discussionmentioning

confidence: 99%

“…T cells reactive against specific antigens (Ags) have emerged as potent targeted immunotherapies for certain cancers and hard-to-treat viral diseases. 1 , 2 Although the immune system harbors different clones of Ag-reactive T cells to endogenously eliminate cancerous or virally infected cells, 3 the body may be caught in a losing battle because of the small number of these cells. Hence, to augment Ag-specific T cell responses in vivo , large-scale in vitro (or ex vivo ) enrichment and expansion of the relevant T cell lines may be a solution.…”

Section: Introductionmentioning

confidence: 99%

“…Hence, to augment Ag-specific T cell responses in vivo , large-scale in vitro (or ex vivo ) enrichment and expansion of the relevant T cell lines may be a solution. This can be achieved via a number of methods including 2 - 4 (1) extraction of Ag-reactive tumor-infiltrating lymphocytes from a tumor graft, (2) enrichment and isolation of endogenous Ag-reactive T cells from peripheral blood, and (3) genetic engineering of autologous T cells using gene vectors encoding a T cell receptor (TCR) or chimeric antigen receptor redirected against the antigen of interest.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Cytotoxicity of WT1-reactive T cells against Wilms tumor: An implication for antigen-specific adoptive immunotherapy

et al. 2023

Self Cite

View full text Add to dashboard Cite

Introduction: T cells that recognize WT1 peptides have been shown to efficiently eliminate WT1-expressing tumor cells. This study was designed to investigate the feasibility of isolating WT1-reactive T cells from peripheral blood mononuclear cells (PBMCs) from healthy donors and patients with Wilms tumor, and to assess the cytotoxicity mediated by these cells against Wilms tumor cells (WiTu cells). Methods: WT1-reactive T cells were enriched and isolated by stimulating PBMCs with a WT1 peptide pool and interferon-γ capture-based immunomagnetic separation (IMS). Using the lactate dehydrogenase release assay, the in vitro cytotoxicity of the isolated cells and standard chemotherapy was evaluated on WiTu cells. Results: Higher proportions of WT1-reactive T cells were isolated from patients with Wilms tumor compared to those isolated from HDs. WT1-reactive T cells produced > 50% specific lysis when co-cultured with WT1+ WiTu cells at the highest effector-to-target (E:T) ratio in this study (i.e., 5:1), compared to <23% when co-cultured with WT1- WiTu cells at the same ratio. WT1-reactive T cells showed anti-tumoral activity in a dose-dependent manner and mediated significantly greater cytotoxicity than the non-WT1-reactive fraction of PBMCs on WT1+ WiTu cells. The cytotoxicity of standard chemotherapy was significantly lower than that of WT1-reactive T cells when co-cultured with WT1+ WiTu cells at E:T ratios of 2:1 and 5:1. Conclusion: WT1-reactive T cells can be effectively enriched from the PBMCs of patients with Wilms tumor. Ex vivo generated WT1-reactive T cells might be considered an adoptive immunotherapeutic option for WT1+ Wilms tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cytotoxicity of WT1-reactive T cells against Wilms tumor: An implication for antigen-specific adoptive immunotherapy

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Baricitinib, a JAK1/2-selective kinase inhibitor, is used in rheumatoid arthritis treatment and severe cases of COVID-19, preventing progression to ARDS (Ai et al 2022 ). Four anti-SARS-CoV-2 monoclonal antibody products have received EUA from US-FDA for non-hospitalized patients, including sotrovimab, bamlanivimab, etesevimab, and “imdevimab and casirivimab” (REGEN-COV) ( https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies/ ; Monzavi et al 2021 ). Thus, developing such novel immunotherapies can target viral infection and improve the clinical outcomes.…”

Section: Covid-19 Therapeutic Approachesmentioning

confidence: 99%

Current clinical status of new COVID-19 vaccines and immunotherapy

Nagpal

Kaushik

et al. 2022

Environ Sci Pollut Res

View full text Add to dashboard Cite

COVID-19, caused by SARS-CoV-2, is a positive-strand RNA belonging to Coronaviridae family, along with MERS and SARS . Since its first report in 2019 in Wuhan, China, it has affected over 530 million people and led to 6.3 million deaths worldwide until June 2022. Despite eleven vaccines being used worldwide already, new variants are of concern. Therefore, the governing bodies are re-evaluating the strategies for achieving universal vaccination. Initially, the WHO expected that vaccines showing around 50–80% efficacy would develop in 1–2 years. However, US-FDA announced emergency approval of the two m-RNA vaccines within 11 months of vaccine development, which enabled early vaccination for healthcare workers in many countries. Later, in January 2021, 63 vaccine candidates were under human clinical trials and 172 under preclinical development. Currently, the number of such clinical studies is still increasing. In this review, we have summarized the updates on the clinical status of the COVID-19 and the available treatments. Additionally, COVID-19 had created negative impacts on world’s economy; affected agriculture, industries, and tourism service sectors; and majorly affected low-income countries. The review discusses the clinical outcomes, latest statistics, socio-economic impacts of pandemic and treatment approaches against SARS-CoV-2, and strategies against the new variant of concern. The review will help understand the current status of vaccines and other therapies while also providing insights about upcoming vaccines and therapies for COVID-19 management. Graphical abstract Supplementary Information The online version contains supplementary material available at 10.1007/s11356-022-22661-1.

show abstract

“…Immunotherapy is defined as utilizing and manipulating the host's immune system to eliminate the affliction. Cell therapies using autologous or allogeneic immune cells have shown potential as a therapeutic approach in solid and hematological malignancies [20] , chronic viral infections ( e.g. HIV) [21] , and refractory viral infections in hematopoietic stem cell transplantation (HSCT) patients [22] , [23] .…”

Section: Immune Cell-based Therapies Against Sars-cov-2 Infectionmentioning

confidence: 99%

An overview of the recent findings of cell-based therapies for the treatment and management of COVID-19

Ghaffari

Kazerooni²,

Salehi-Najafabadi

2021

International Immunopharmacology

View full text Add to dashboard Cite

An outlook on antigen-specific adoptive immunotherapy for viral infections with a focus on COVID-19

Abstract: Graphical abstract Adoptive immunotherapy options currently under trial for COVID-19

Cited by 8 publications

References 95 publications

Cytotoxicity of WT1-reactive T cells against Wilms tumor: An implication for antigen-specific adoptive immunotherapy

Cytotoxicity of WT1-reactive T cells against Wilms tumor: An implication for antigen-specific adoptive immunotherapy

Current clinical status of new COVID-19 vaccines and immunotherapy

An overview of the recent findings of cell-based therapies for the treatment and management of COVID-19

Contact Info

Product

Resources

About